Terminology Service < Semantic Lookup Platform

All terms in MESH

Label	Id	Description
XmyogU2 protein, Xenopus	C446023
New Orleans	D055820	[City in Orleans Parish (county), largest city in state of LOUISIANA. It is located between the Mississippi River and Lake Pontchartrain.]
Louisiana	D008145	[State bounded by Arkansas on the north, by Mississippi on the east, the Gulf of Mexico on the south and Texas on the west.]
Poetry	D055821	[Works that consist of literary and oral genre expressing meaning via symbolism and following formal or informal patterns.]
Cookbook	D055823	[Collection of recipes or instructions for preparation of food and organization of meals.]
Formulary	D055824	[A list of drugs permitted to be dispensed., A list of the drugs that satisfy the priority health care needs of the majority of a population. According to the World Health Organization, these drugs should be available at all times in adequate amounts and in appropriate dosage forms and quality, at a price the community can afford., Work that consists of lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations., A list of medications that are covered by a prescription drug insurance plan.]
Pole protein, mouse	C485610
IndC protein, Erwinia chrysanthemi	C446046
Akap3 protein, mouse	C485611
IndA protein, Erwinia chrysanthemi	C446047
TBL1Y protein, human	C485612
btuF protein, E coli	C446048
Tbl1x protein, mouse	C485613
AcsF protein, Rubrivivax gelatinosus	C446049
Kdm5b protein, mouse	C485614
Monocytes, Activated Killer	D016260	[Monocytes made cytotoxic by IN VITRO incubation with CYTOKINES, especially INTERFERON-GAMMA. The cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients.]
Ripk3 protein, mouse	C485615
cx55.5 protein, zebrafish	C485616
Postpoliomyelitis Syndrome	D016262	[A syndrome characterized by new neuromuscular symptoms that occur at least 15 years after clinical stability has been attained in patients with a prior history of symptomatic poliomyelitis. Clinical features include new muscular weakness and atrophy of the limbs, bulbar innervated musculature, and muscles of respiration, combined with excessive fatigue, joint pain, and reduced stamina. The process is marked by slow progression and periods of stabilization. (From Ann NY Acad Sci 1995 May 25;753:68-80)]
Muscular Disorders, Atrophic	D020966	[Disorders characterized by an abnormal reduction in muscle volume due to a decrease in the size or number of muscle fibers. Atrophy may result from diseases intrinsic to muscle tissue (e.g., MUSCULAR DYSTROPHY) or secondary to PERIPHERAL NERVOUS SYSTEM DISEASES that impair innervation to muscle tissue (e.g., MUSCULAR ATROPHY, SPINAL).]